DrugPatentWatch Database Preview
Drugs in Development Information for Gefapixant
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Gefapixant?
Gefapixant is an investigational drug.
There have been 8 clinical trials for Gefapixant.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 14th 2018.
The most common disease conditions in clinical trials are Cough, Endometriosis, and Respiratory Tract Infections. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Afferent Pharmaceuticals, Inc., and [disabled in preview].
There are fourteen US patents protecting this investigational drug and one hundred and fifteen international patents.
Summary for Gefapixant
US Patents | 14 |
International Patents | 115 |
US Patent Applications | 22 |
WIPO Patent Applications | 6 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 2 (2018-03-14) |
Vendors | 14 |
Recent Clinical Trials for Gefapixant
Title | Sponsor | Phase |
---|---|---|
A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) | Merck Sharp & Dohme Corp. | Phase 3 |
A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034) | Merck Sharp & Dohme Corp. | Phase 2 |
Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013) | Merck Sharp & Dohme Corp. | Phase 2 |
Clinical Trial Summary for Gefapixant
Top disease conditions for Gefapixant
Top clinical trial sponsors for Gefapixant
US Patents for Gefapixant
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Gefapixant | Start Trial | Methods and compositions for treating diseases and conditions | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | Start Trial |
Gefapixant | Start Trial | Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | Start Trial |
Gefapixant | Start Trial | Diaminopyrimidines as P2X.sub.3 and P2X.sub.2/3 antagonists | Roche Palo Alto LLC (Palo Alto, CA) | Start Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Gefapixant
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Gefapixant | European Patent Office | 3164132 | 2034-07-03 | Start Trial |
Gefapixant | World Intellectual Property Organization (WIPO) | 2016004358 | 2034-07-03 | Start Trial |
Gefapixant | Australia | 2014308606 | 2033-08-23 | Start Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |